Bactolife

Denmark
Kongens Lyngby, Capital Region, Denmark, 2800

Company profile

Bactolife company profile

Bactolife is a biotechnology company that develops biological solutions based on proprietary binding protein technology to support gut health by targeting and neutralizing harmful microbial activity without disrupting beneficial microbiota. Its platform produces precision-designed proteins that act on specific toxins in the gastrointestinal system, enabling applications in food, feed, dietary supplements, and health ingredients for humans and animals. Bactolife’s innovations aim to reduce the risk of gastrointestinal infections and decrease reliance on traditional antibiotics by offering alternative mechanisms that strengthen the microbiome. The company collaborates with partners to advance product development, conduct clinical studies, and scale manufacturing for broader market delivery. Users of its technology include product developers, nutrition brands, and animal health stakeholders seeking science-based gut health solutions. Bactolife continues to expand its ingredient offerings and global deployment of its Binding Protein platform to address emerging health and microbiome needs.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2017-01-01, Year

Headquarters

Postal code
2800
Country code
DK
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
4
Total equity funding
$76.5M
Last funding
Series B / $35.2M / 2026-01-06
Last equity funding
Series B / $35.2M
Investors
8
Lead investors
5
Founders
5
Articles
29

Founders and investors

Founders

Andreas LaustsenDavid KauffmannMads LaustsenPer FalholtSandra Wingaard Thrane

Lead investors

ATHOSBill & Melinda Gates FoundationCross-Border Impact VenturesExport and Investment FundNovo Seeds

Investors

ATHOSBill & Melinda Gates FoundationCross-Border Impact VenturesExport and Investment FundNovo Holdings